Sofia Lindqvist
Media & Financial Communications Manager
Email: sofia.lindqvist@molnlycke.com
Phone: +4672 255 35 09
Mölnlycke Health Care reaches 100% renewable electricity target
Mölnlycke, a world leading MedTech company, has secured 100% renewable electricity for all its established and new manufacturing sites and its headquarters, reaching its first near-term SBTi (Science Based Targets initiative)-validated target.
Gothenburg, Sweden. 28 January 2025. “This is a significant milestone in Mölnlycke’s commitment to halving Scope 1 and 2 greenhouse gas emissions by 2030” said Caterina Camerani, VP Sustainability at Mölnlycke. “It propels us towards our vision of building a sustainable healthcare manufacturing ecosystem.”
A major enabler in reaching the goal was signing two virtual Power Purchase Agreements (vPPAs) for the regions where the company has the highest manufacturing footprint. To cover electricity consumption for the sites in the European Union, Mölnlycke signed a long-term vPPA committing to purchasing renewable electricity generated in Mutkalampi, the largest wind farm in Finland. The three manufacturing plants in Malaysia will handle their renewable electricity needs through a similar vPPA from a newly established solar power plant in Bukit Kayu Hitam, Malaysia.
In addition, Mölnlycke continues to invest in on-site generation of solar energy with manufacturing sites in Malaysia and the UK having completed the installation of rooftop solar panels and the installation on factories in Thailand ongoing.
The remaining electricity consumption needs for the established manufacturing sites in Thailand, the UK and the US, as well as the newly established plant in the Kingdom of Saudi Arabia are met through Renewable Energy Certificates (RECs). As stated in the near-term goal validated by SBTi, Mölnlycke will continue active sourcing of renewable electricity through 2030.
For more information, please contact:
Latest news
-
Mölnlycke Health Care publishes Annual report for 2024
Gothenburg, Sweden. 1 April 2025. Today Mölnlycke Health Care has published its Annual report for 2024, including the sustainability report.
-
New study demonstrates the potential benefits of dressing regime improvements in delivering value-based chronic wound care
-
Mölnlycke Health Care announces launch of the 2025 Future Summit
Mölnlycke Health Care’s Wound Care business area is delighted to announce the launch of its 2025 Future Summit, an educational event bringing together healthcare professionals (HCPs) from across Europe, the Middle East, and Africa (EMEA).
-
Mölnlycke Health Care announces USD 8 million investment in diabetic foot ulcer management system company Siren
-
Mölnlycke Health Care wins Swedish Sustainability Tech award
Mölnlycke is proud to announce that it has been awarded the Capgemini Swedish Sustainability Tech Award 2024 for Mölnlycke ProcedurePak® trays. This accolade recognises the company’s innovative practices and dedication to revolutionise healthcare for people and planet.
-
Mölnlycke Health Care appoints Guillaume Joucla as Chief Financial Officer
Joucla’s extensive experience and insights to drive financial strategy and growth initiatives.
-
Mölnlycke Health Care and Operation Smile help to change people's lives with newly inaugurated cleft care centre in Philippines
The centre is expected to serve 10,000 patients in the region with transformative cleft care in the first three years of operations.
-
Mölnlycke® Health Care and Transdiagen announce research collaboration to drive innovation in wound care
-
Mölnlycke® Health Care acquires P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturising
Today, Mölnlycke Health Care, a world leading MedTech company, specialising in wound care and wound management, announces the completion of the acquisition of P.G.F. Industry Solutions GmbH, the Austrian manufacturer of Granudacyn® wound cleansing and moistening solutions.